Learn more about the Affinity team Michael Koehler, MD Affinity's Medical Director Real patients , real results Started my journey on December 9, 2023
It is a thoughtfully staged roadmap designed to make a powerful medication accessible and tolerable for real people managing real weight and metabolic challenges
Cardiovascular benefit: In adults with type 2 diabetes who have established cardiovascular risk, a GLP-1 RA may provide cardiovascular benefit, independent of baseline A1C
The data indicate that dysregulated serotonin metabolism may be a critical role in PBH [33]
Tirzepatide and semaglutide have FDA-approved uses and are available by prescription for appropriate patients
Side Effects to Consider Both medications are generally well-tolerated, but they can cause mild side effects such as: Nausea Diarrhea Decreased appetite Fatigue These effects are typically temporary and decrease as your body adjusts to the medication